publication . Article . Other literature type . 2018

Profiling Prostate Cancer Therapeutic Resistance.

Cameron A. Wade; Natasha Kyprianou;
Open Access English
  • Published: 19 Mar 2018 Journal: International Journal of Molecular Sciences, volume 19, issue 3 (eissn: 1422-0067, Copyright policy)
  • Publisher: MDPI
The major challenge in the treatment of patients with advanced lethal prostate cancer is therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy. Overriding this resistance requires understanding of the driving mechanisms of the tumor microenvironment, not just the androgen receptor (AR)-signaling cascade, that facilitate therapeutic resistance in order to identify new drug targets. The tumor microenvironment enables key signaling pathways promoting cancer cell survival and invasion via resistance to anoikis. In particular, the process of epithelial-mesenchymal-transition (EMT), directed by transforming growth factor-β (TGF-β), confers stem...
free text keywords: Review, epithelial plasticity, androgen receptor, tumor landscape, metabolic changes, Biology (General), QH301-705.5, Chemistry, QD1-999, Physical and Theoretical Chemistry, Inorganic Chemistry, Organic Chemistry, Spectroscopy, Molecular Biology, Catalysis, General Medicine, Computer Science Applications
133 references, page 1 of 9

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7-30. [CrossRef] [PubMed]

2. Crawford, E.D.; Petrylak, D.; Sartor, O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol. Oncol. 2017, 35S, S1-S13. [CrossRef] [PubMed]

3. Higano, C.S.; Crawford, E.D. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol. Oncol. 2011, 29 (Suppl. 6), S1-S8. [CrossRef] [PubMed]

4. Kirby, M.; Hirst, C.; Crawford, E.D. Characterising the castration-resistant prostate cancer population: A systematic review. Int. J. Clin. Pract. 2011, 65, 1180-1192. [CrossRef] [PubMed]

5. Scher, H.I.; Solo, K.; Valant, J.; Todd, M.B.; Mehra, M. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 2015, 10, e0139440. [CrossRef] [PubMed]

6. Thompson, I.M.; Pauler, D.K.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Parnes, H.L.; Minasian, L.M.; Ford, L.G.; Lippman, S.M.; Crawford, E.D.; et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 2004, 350, 2239-2246. [PubMed]

7. National Institutes of Health (NIH) Website. Prostate-Specific Antigen (PSA) Test. Available online: https: // (accessed on 17 December 2017).

8. Epstein, J.I.; Allsbrook, W.C., Jr.; Amin, M.B.; Egevad, L.L.; Committee, I.G. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005, 29, 1228-1242. [CrossRef] [PubMed]

9. Epstein, J.I.; Amin, M.B.; Reuter, V.E.; Humphrey, P.A. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2017, 41, e1-e7. [CrossRef] [PubMed]

10. Ayala, G.; Thompson, T.; Yang, G.; Frolov, A.; Li, R.; Scardino, P.; Ohori, M.; Wheeler, T.; Harper, W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 2004, 10, 6572-6578. [CrossRef] [PubMed]

11. Goldstein, N.S. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol. 2002, 117, 471-477. [CrossRef] [PubMed]

12. Henshall, S.M.; Quinn, D.I.; Lee, C.S.; Head, D.R.; Golovsky, D.; Brenner, P.C.; Delprado, W.; Stricker, P.D.; Grygiel, J.J.; Sutherland, R.L. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 2001, 7, 544-550. [PubMed]

13. Brawer, M.K. Prostatic intraepithelial neoplasia: An overview. Rev. Urol. 2005, 7 (Suppl. 3), S11-S18. [PubMed] [OpenAIRE]

14. Siegal, J.A.; Yu, E.; Brawer, M.K. Topography of neovascularity in human prostate carcinoma. Cancer 1995, 75, 2545-2551. [CrossRef] [OpenAIRE]

15. Huggins, C.; Hodges, C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 2002, 168, 9-12. [CrossRef] [OpenAIRE]

133 references, page 1 of 9
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue